Improving HIV Pre Exposure Prophylaxis (PrEP) uptake and initiation: process evaluation and recommendation development from a national PrEP programme
1School of Health & Life Sciences, Glasgow Caledonian University, Glasgow UK Cowcaddens Road, Glasgow, G4 0BA
2Sandyford Sexual Health Services, NHS Greater Glasgow & Clyde, 6 Sandyford Place, Glasgow, G3 7NB
3Institute for Global Health, University College London, London UK, Mortimer Market Centre, London, WC1E 6JB
4HPA Health Protection Services, Public Health England, London, UK, 61 Colindale Avenue, London, NW9 5EQ
5College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK, University Avenue, Glasgow, G12 8QQ
6Centre for Biomedicine, Self & Society, University of Edinburgh, Edinburgh, UK, Usher Institute, Teviot Place, Edinburgh, EH8 9AG
7Chalmers Sexual Health Centre, NHS Lothian, Edinburgh, UK, 2A Chalmers Street, Edinburgh, EH3 9ES
8Chief Medical Officer Directorate, Scottish Government, Edinburgh, UK, St Andrew’s House, Regent Road, Edinburgh, EH1 3DG
9Institute for Social Science Research, The University of Queensland, Brisbane, Australia, Brisbane St Lucia, QLD 4072
10School of Psychological Sciences & Health, University of Strathclyde, Glasgow, UK, 16 Richmond Street, Glasgow G1 1XQ
*Corresponding author: Claudia Estcourt (claudia.estcourt@gcu.ac.uk)Abstract
Background
HIV pre-exposure prophylaxis (PrEP) is key to HIV transmission elimination but implementation is challenging and under-researched. We undertook a process evaluation of the first two years of a national PrEP programme to explore barriers and facilitators to implementation and to develop recommendations to improve implementation, focussing on PrEP uptake and initiation.
Methods
Stage 1 involved semi-structured telephone interviews and focus groups (09/2018-07/2019) with geographically and demographically diverse patients seeking/using/declining/stopping PrEP (n=39), sexual healthcare professionals (n= 54), community-based organisation service users (n=9) and staff (n=15) across Scotland. We used deductive thematic analysis, to derive and then map key barriers and facilitators to priority areas that experts agreed would enhance initiation and uptake. In Stage 2 we used analytic tools from implementation science to systematically generate evidence-based, theoretically-informed recommendations to enhance uptake and initiation of PrEP.
Results
Barriers and facilitators were multi-levelled and interdependent. Barriers included the rapid pace of implementation without additional resource, and a lack of familiarity with PrEP prescribing. Facilitators included opportunities for acquisition of practice-based knowledge and normalisation of initiation activities. We refined our 68 “long-list” recommendations to 41 using expert input and the APEASE criteria. Examples include: provision of PrEP in diverse settings to reach all in need; co-produced, culturally sensitive training resources for healthcare professionals, with focused content on non-daily dosing; meaningful collaborative working across all stakeholders.
Conclusions
These evidence-based, theory informed recommendations provide a robust framework for optimising PrEP uptake and initiation in diverse settings to ensure PrEP reaches all who may benefit.
Summary for table of contents
Zero new HIV infections could become a reality if HIV pre-exposure prophylaxis (PrEP) programmes are successfully implemented but the World Health Organisation recognizes that large scale roll out is challenging.
We used implementation science research tools in novel ways to evaluate one of the world’s first national PrEP programmes, to develop evidence-based recommendations for use across a range of settings to improve PrEP uptake and initiation.
Adopting these recommendations could enable governments and societies to better address HIV prevention goals.
Article notes
Competing Interest Statement
CSE reports research grants from National Institute of Health Research UK, Chief Scientist Office of Scotland, Engineering and Physical Sciences Research Council, UK Clinical Research Collaboration, Health Protection Scotland, European Centres for Disease Control. JM reports no competing interests. JS reports no competing interests RN reports research grants from National Institute of Health Research UK, Chief Scientist Office of Scotland and non-executive director membership of the Board of Public Health Scotland from April 2020. IY reports no competing interests JF reports no competing interests DC reports no competing interests NS reports no competing interests LM reports no competing interests JD reports no competing interests PF reports research grants from National Institute of Health Research UK, Australian Research Council and Chief Scientist Office of Scotland.
Funding Statement
The funders had no role in study design, collection, management, analysis and interpretation of data; writing of the report and the decision to submit the report for publication. This work presents independent research funded by the Scottish Government Chief Scientist Office (reference number HIPS/17/47). LM was funded by the UK Medical Research Council and Chief Scientist Office of the Scottish Government Health and Social Care Directorates at the MRC/CSO Social & Public Health Sciences Unit, University of Glasgow (MC_UU_12017/11, SPHSU11; MC_UU_00022/3, SPHSU18).
Background
HIV pre-exposure prophylaxis (PrEP), in which people take antiretroviral medication to prevent HIV acquisition, is a major advance in biomedical prevention of HIV. In clinical trials, orally administered PrEP has been shown to reduce the risk of HIV acquisition by 44-97% (1-4). Although PrEP is becoming increasingly available, insights from real-world implementation studies are limited (5-7). The World Health Organization and others acknowledge the importance of making PrEP available for safe, effective prevention outside clinical trial settings as key to realising its potential to end HIV epidemics (8,9). Implementation science tools could help unlock the full potential of PrEP (10) to assist with the elimination of HIV transmission (9).
Scotland became one of the first countries worldwide to implement a national PrEP programme (11). At the time, there were around 4600 people living with HIV attending specialist care in Scotland (12) and 228 people newly diagnosed with HIV each year, half of whom were gay, bisexual, and other men who have sex with men (GBMSM) (13). From July 2017, PrEP and all associated medical monitoring were made available free at point of access, as part of broader HIV combination prevention and sexual health care, almost exclusively through sexual health clinics, to those at greatest risk of HIV acquisition (14). Prescribing followed specialist association guidance (15), but services developed their own local models of delivery, largely within existing budgets. These broadly involved: [1] identifying a patient as a PrEP candidate; [2] provision of PrEP information, baseline screening for HIV and other blood borne viruses (BBVs), sexually transmitted infections (STIs), and renal function; [3] prescribing and dispensing PrEP; and [4] regular in person reviews for HIV, BBV, and STI testing, renal monitoring, adherence support, wider sexual health promotion, and PrEP prescribing (15). Quantitative outcomes from the national PrEP Programme have been reported as part of routine surveillance (12-14) and through detailed epidemiology (6).
We conducted a process evaluation of the first two years of Scotland’s PrEP programme. Our approach divided the PrEP care cascade into three sections; awareness and access (16), initiation and uptake and adherence and retention in care (17). Here we focussed on uptake and initiation of PrEP.
We addressed the following research questions:
- Within PrEP care pathways where exactly should we intervene (priority areas) to optimise uptake and initiation?
- What are the barriers and facilitators to optimising implementation within these priority areas?
- Which evidence-based and theoretically informed recommendations could improve the implementation of PrEP uptake and initiation?
Methods
As described elsewhere (16-17), Stage 1 is a retrospective qualitative process evaluation within a larger natural experimental design study evaluating PrEP implementation in Scotland (research questions 1 and 2), and Stage 2 involves development of recommendations to improve PrEP uptake and initiation, using systematic intervention development approaches (research question 3).
Data collection
Participants
We used multi-perspective purposive sampling to understand the implementation of PrEP uptake and initiation from diverse viewpoints. In total, 117 participants took part in individual semi-structured telephone interviews (n=71) or in one of 10 group discussions (n=46) (September 2018-July 2019). The sample comprised: 39 patients; 54 healthcare professionals; nine non-governmental organisation (NGO) service users; and 15 NGO staff from across Scotland. All NGOs had an HIV prevention remit and served GBMSM, trans, and/or Black African communities. Group discussions included one type of stakeholder only.
Patients were either using PrEP (n=23, 59%) or had declined (n=5, 13%), stopped (n=6, 15%), or been assessed as ineligible (n=5, 13%) for PrEP. PrEP users included those who took PrEP daily, event-based or both ways. They ranged in age from 20-72 years with just over half (n=21, 54%) between 25-34 years. All self-identified as gay or bisexual men, the majority of whom (n=34, 87%) were cisgender. Almost all were of ‘White British’ (n=31, 80%) or ‘Other White’ (n=7, 18%) ethnicity. Two thirds had a university degree (n=26, 67%) and the majority were in employment (n=34, 87%). The patient areas of residence reflected a mix of relative affluence and deprivation although the most (n=5, 16.7%) and least (n=3, 10%) deprived quintiles (according to Scottish Index of Multiple Deprivation (SIMD), which divides areas into five subgroups according to the extent to which an area is “deprived” (18)) were under-represented and patients predominantly resided in the middle three quintiles (73%) (data missing for 9 participants). Healthcare professionals were all involved in PrEP implementation in a mix of rural (n=12, 22%), semi-rural/urban (n=8, 15%), or urban (n=34, 63%) settings, largely reflecting the wider Scottish population distribution. They included specialist sexual health doctors and nurses of various grades, some with national PrEP roles, PrEP prescribing general practitioners (who prescribed PrEP on the Scottish islands), health promotion officers, a midwife, and a clinical secretary responsible for PrEP-related administration. NGO service users were all of Black African ethnicity, predominantly cis-gender women, and not using PrEP.
Recruitment
Healthcare professionals offered patients the opportunity to take part in the study during routine consultations taking place in four of the 14 regional health boards (responsible for the protection and improvement of their population’s health) providing over 90% of PrEP related care in Scotland. NGO service users who were either engaged with NGOs and attending sexual health clinics (classed as patients above) or only engaged with NGO services (classed as NGO service users above) were invited to participate via interactions with NGO staff. We recruited these and other NGO staff and healthcare professionals across all of Scotland’s 14 regional health boards by email invitation.
Procedure
All participants provided informed verbal or written consent immediately prior to the interviews /group discussions. We collected data with the aid of a topic guide that included open-ended questions designed to explore participants’ experiences and perceptions of uptake and initiation of PrEP, rather than questions based on any theoretical concepts anticipated to influence implementation. Where possible within the group discussions, dialogue between participants was encouraged rather than between facilitators and participants. All participants talked from their own and others’ perspectives; data were taken at face value. Patients were offered a £30 shopping voucher as reimbursement for their time.
Data collection was led by JM, with input from experienced qualitative researchers, PF, IY, and JF. JM, PF, IY, and JF reviewed and discussed early transcripts for quality assurance purposes. All interviews and group discussions were audio recorded, transcribed verbatim, anonymised, and imported into NVivo software for analysis.
Data analysis
Stage 1
Research Question 1: Within PrEP care pathways where exactly should we intervene (priority areas) to optimise uptake and initiation?
Firstly, we used the Action, Actor, Context, Target, Time framework (19), to conceptualise the sequential actors, actions, settings, and processes that constituted PrEP adherence and retention in care. Secondly, we iteratively created a series of visualisations of the overall behavioural system of PrEP adherence and retention in care using available UK guidance on best clinical practice in PrEP provision (12) and transcripts of early interviews and group discussions. Thirdly, we comprehensively assessed the breadth and depth of data relating to the patient pathway through PrEP adherence and retention in care. Finally, we (PF & JM) ranked the most important areas which were considered to be amenable to change to create priority areas for intervention. Then research team members with real-world clinical experience of providing PrEP services in assorted settings (CSE, RN, JS) provided further input resulting in the identification of nine final priority areas for recommendation development.
Stage 2
Research question 3: Which evidence-based and theoretically informed recommendations could improve PrEP adherence and retention in care?
We treated each of the priority areas independently and analysed each separately. Firstly, we entered the key barriers and facilitators into a matrix. Secondly, we used the Behaviour Change Wheel (BCW) approach (21), and systematically coded the key barriers and facilitators for each priority area using the Theoretical Domains Framework (TDF) (22). Finally, we specified corresponding Intervention Functions (broad ways of intervening relevant to the theoretical domains) and used the Behaviour Change Technique (BCT) and corresponding Taxonomy (BCTTV1v1) (23) to describe, in detail and using a standardised language, potential intervention content that may be helpful to operationalise the Intervention Functions, address key barriers and facilitators, and enhance future PrEP implementation. This created an initial “long-list” of recommendations. All coding and drafting of recommendations were completed by JM and double-checked for accuracy, validity, and credibility by PF. Any disagreements were discussed until consensus was reached.
Finally, clinical expert team members (CE, RN, JS) scrutinised, sense-checked, and shortlisted the long list of initial recommendations using the APEASE criteria (24). This resulted in the introduction of some new recommendations, in addition to minor amendments to or merging/deleting of existing recommendations.
Ethical considerations
The Glasgow Caledonian University Research Ethics Committee (HLS/NCH/17/037, HLS/NCH/17/038, HLS/NCH/17/044) and the South East Scotland National Health Service Research Ethics Committee (18/SS/0075, R&D GN18HS368) provided ethical approval.
Results
Research Question 1: Within PrEP care pathways where exactly should we intervene (priority areas) to optimise uptake and initiation?
Nine priority areas for intervention (black) were identified from the wider range of potential areas of focus (Figure 1). Each potential area forms part of a typical patient pathway at the start of PrEP care. The priority areas involve two actors (sexual healthcare professionals (HCPs) and potential PrEP users (patients)).
Research Question 3: Which evidence-based and theoretically informed recommendations should improve future PrEP uptake and initiation?
Analysis of the main barriers and facilitators to each priority area enabled us to systematically theorise what was working well in relation to implementation, and also what was not. We were then able to formulate specific tailored recommendations to enhance the future implementation of each of the priority areas in both general terms (intervention functions) and highly specific terms (operationalised BCTTV1s) (Table 2). Full details of our underpinning analysis are provided within supplementary files.
Discussion
Complex multi-levelled factors shaped PrEP implementation. Nine specific areas of the PrEP care cascade involved in initiation and uptake of PrEP were both amenable to change and prioritised for improvement. The corresponding barriers and facilitators were multi-levelled and interdependent. Many were psychosocial, relating directly to the way staff or patients thought and felt; others related to the organisation of services, wider issues of access to support and training, and factors relating to the environmental infra-structure of services. Using tools from implementation science, we systematically generated highly specific, theoretically informed and evidence-based ways of optimising PrEP implementation in the future. Examples include: provision of PrEP in diverse settings to reach all in need; co-produced, culturally sensitive training resources for healthcare professionals, with focused content on non-daily dosing; meaningful collaborative working across all stakeholders.
To date, several attempts have been made to conceptualise the implementation of PrEP but these have been largely broad and descriptive, typically categorising the whole of PrEP care into four or five large steps within a continuous, linear ‘care cascade’ (25-28). Published studies have tended to focus on using these high-level steps to audit or quantify PrEP implementation, seeking to identify and understand key points of attrition within particular populations and associated health care systems (29). There are numerous examples of PrEP prescribing guidance (15,30-31), but fewer published studies specifically address the implementation of PrEP routine care pathways and services. A scoping review of PrEP delivery models (32) created a comprehensive inventory of existing models, but did not specifically focus on delivery of the detailed steps of the PrEP cascade within the models described. A review of PrEP implementation identified multiple barriers to PrEP uptake, some of which mirrored those we described (33). The authors proposed multilevel interventions to target these barriers but acknowledge that proposed interventions do not always align to specific barriers.
In contrast, no work to date has used conceptualisations of the care cascade as a starting point for systematic, focussed service improvement whilst explicitly using theory and evidence to enhance implementation. We directly addressed this gap by taking a single key step of the PrEP care cascade, the ‘uptake and initiation of PrEP’, and focussed on it as an area in need of intervention development to enhance future implementation. We derived recommendations (interventions) directly from the barriers and facilitators at each priority area.
Some recommendations warrant additional comment. In relation to ‘engaging HCPs with PrEP as an acceptable approach to HIV prevention’, we highlight the need to address both structural and psychosocial issues. We also emphasise the importance of considering financial and other resources as well as the timescale for implementation. These factors are likely to be central to HCP engagement which in turn is central to patient uptake. We also recommend a multileveled national infrastructure to promote, coordinate, and monitor HCP engagement with PrEP and highlight how these structural initiatives could be bolstered by a range of local initiatives such as engaging staff through local “PrEP champions”. The barriers these recommendations are designed to overcome were strikingly similar to those reported in a number of studies within Pinto et al’s recent review (33).
In relation to ‘potential PrEP users accurately reporting their HIV risk behaviour…”, we found that depending on the cultural context, it may be important to educate and persuade HCP about the ‘bigger picture’ of PrEP provision and overcome any residual moralism and stigma relating to sex, homophobia, or racism which has also been described in other studies (33-34). Stigma is well recognised as a potent barrier to accessing HIV testing, prevention and care and it also might inhibit the full disclosure of HIV acquisition risk factors such as stigmatised sexual behaviours or partner numbers relevant to PrEP offer and uptake. Stigma may also apply to and inhibit the taking of PrEP itself (35-37). We recommend close partnership work between sexual health services, CBOs and PrEP users to enable sensitive, culturally appropriate conversations around PrEP, and to help HCPs improve their cultural competencies. The strongly supported health care and community-level “PrEP-positive” ethos described by our participants seems highly appropriate and would need to be extended to all settings in which PrEP may be provided in the future, particularly those in which sexual health is less familiar.
Our findings suggest that the ‘PrEP eligibility criteria’ which were used by HCPs to help identify people who might benefit most from PrEP (26), should be reframed and understood as needs-based approaches to HIV prevention, conveying the pros and cons of PrEP so that it can be extended to all who could benefit. This could largely remove the issue that criteria are less sensitive for identifying people from certain groups or racial backgrounds as also reported in other countries (38).
A large epidemiological analysis published after this study showed that Scottish implementation models strongly favour GBMSM and have limited reach into other key vulnerable populations (6,14). In parallel, the characteristics of people newly diagnosed with HIV in Scotland have changed since the introduction of PrEP and now people are more likely to have acquired HIV though heterosexual sex and to be non-white indigenous than in the pre-PrEP era (14,39), similar to findings from Australia (40). As noted in our recommendations and by others, reaching all groups that could benefit from PrEP is essential (9); Several studies provide explanations for low PrEP uptake in some key vulnerable populations. Among women of colour in the UK, important factors were low awareness of PrEP, feelings of stigma related to HIV itself and attending sexual health clinics, and a preference for trusted community settings for discussion about HIV testing and prevention (35,41)). Among people who inject drugs in Scotland, awareness of PrEP was low but some would find PrEP appealing if provided within familiar settings such as outreach drug services (42). Very few trans people have accessed PrEP in Scotland (12). International studies suggest that the need for PrEP among this group is high but important barriers to access preclude uptake (36,43). Restricting PrEP provision to sexual health clinics probably deters some trans people who could benefit (44). Additional or tailored recommendations to enhance PrEP uptake and initiation for people from vulnerable populations are needed as evidence accrues.
We used a novel, rigorous approach to developing recommendations which is not typical of approaches to enhancing implementation. The resulting recommendations are anchored in the evidence and theory-driven (22) and are specified using a standardised language to describe intervention content in detail (i.e., intervention functions and behaviour change techniques (23)). Typically, the initial stages of the PrEP care cascade involve a complex patient journey, marked by setting-specific interactional dynamics and a series of interdependent joint and individual behaviours. Our adoption of a behavioural lens, and the subsequent systematic development of highly specific ways to enhance implementation, meant we re-conceptualised this patient journey as a series of distinct and sequential behaviours. This approach led to costs and benefits; where we gained through this behavioural specificity and our ability to specify future recommendations in great detail (e.g. behavioural change techniques), there was duplication of effort to detail shared antecedents to the varied behaviours.
We focussed on one national context and although findings are likely to be generalisable to similar settings, it is uncertain how recommendations might apply in very different contexts. In particular, as all PrEP care was free of charge, participants did not face the financial barriers reported from some settings (45). Very few people in Scotland on PrEP are not GBMSM (13) and our findings lack specificity for other groups. A high proportion of PrEP user participants had a university qualification and while representative of those on PrEP in Scotland, the sample under-represents those with lower health and PrEP literacy who may have other needs and preferences for accessing PrEP care. Furthermore, the COVID-19 pandemic led to a reconfiguration of some sexual health and PrEP services and our findings may be more or less relevant as a result. Our evaluation took place relatively early in the PrEP programme which probably magnifies early stage issues which become less important as familiarity increases.
To support individuals and populations to fully benefit from PrEP we must overcome the considerable challenges of large-scale implementation (31). Here, we combined qualitative data from multiple viewpoints and used multiple analytic tools to systematically detail useful insights concerning initiation and uptake from the first two years of Scottish PrEP implementation. To our knowledge, we present the first evidence-based and theory-informed recommendations which can be used flexibly across a range of settings to improve PrEP initiation and uptake. Our findings will inform future Scottish implementation of PrEP (46) and could usefully contribute to the global public health priority of elimination of HIV transmission by 2030 (31,47).
Supporting information
Data Availability
Due to the sensitive nature of the questions asked in this study, survey respondents were assured raw data would remain confidential and would not be shared.
Declarations
Ethics approval and consent to participate
The study received ethical approval from the Glasgow Caledonian University Research Ethics Committee (REC) (HLS/NCH/17/037, HLS/NCH/17/038, HLS/NCH/17/044) and the South East Scotland NHS REC (18/SS/0075, R&D GN18HS368)
Consent for publication
Not applicable
Data Availability Statement
Due to the sensitive nature of the questions asked in this study, survey respondents were assured raw data would remain confidential and would not be shared.
Conflicts of interest
CSE reports research grants from National Institute of Health Research UK, Chief Scientist Office of Scotland, Engineering and Physical Sciences Research Council, UK Clinical Research Collaboration, Health Protection Scotland, European Centres for Disease Control.
JM reports no competing interests.
JS reports no competing interests
RN reports research grants from National Institute of Health Research UK, Chief Scientist Office of Scotland and non-executive director membership of the Board of Public Health Scotland from April 2020.
IY reports no competing interests
JF reports no competing interests
DC reports no competing interests
NS reports no competing interests
LM reports no competing interests
JD reports no competing interests
PF reports research grants from National Institute of Health Research UK, Australian Research Council and Chief Scientist Office of Scotland
Funding
The funders had no role in study design, collection, management, analysis and interpretation of data; writing of the report and the decision to submit the report for publication. This work presents independent research funded by the Scottish Government Chief Scientist Office (reference number HIPS/17/47). LM was funded by the UK Medical Research Council and Chief Scientist Office of the Scottish Government Health and Social Care Directorates at the MRC/CSO Social & Public Health Sciences Unit, University of Glasgow (MC_UU_12017/11, SPHSU11; MC_UU_00022/3, SPHSU18).
Acknowledgements
We are very grateful to the users, patients and staff of sexual health services in all 14 Health Boards, Drs Ruth Holman, Dan Clutterbuck, Maggie Gurney, Nil Banerjee, Pauline McGough, Daniela Brawley, Kirsty Abu-Rajab, Hame Lata, Anne McLellan, Alison Currie, Sharon Cameron, Hilary MacPherson, Janice Irvine, Graham Leslie, Ciara Cunningham, Maggie Watts. We thank staff and users of HIV Scotland; Waverley Care (SX Project and African Health Project); THT Scotland; Hwupenyu Health and Wellbeing; and Scottish Trans Alliance. We thank Nathan Sparling and Jacqueline Gray for their contributions to the research process.